<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02252198</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00085221</org_study_id>
    <secondary_id>NA_00085221</secondary_id>
    <nct_id>NCT02252198</nct_id>
  </id_info>
  <brief_title>Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests</brief_title>
  <acronym>FIND</acronym>
  <official_title>Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests for the Diagnosis of Pulmonary Tuberculosis in Comparison to Geneexpert MTB/RIF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess sensitivity and specificity of two nucleic acid amplification tests, namely Epistem&#xD;
      Genedrive® and MolbioTruenat™ in raw sputum compared to the WHO-endorsed GeneXpert® MTB/RIF&#xD;
      assay using a gold standard of four cultures&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Estimate the accuracy of the Epistem Genedrive® and MolbioTruenat™ in raw sputum and in&#xD;
           sputum pellets.&#xD;
&#xD;
        -  Assess the operational feasibility of Epistem Genedrive® and MolbioTruenat™&#xD;
&#xD;
        -  Determine and compare costs between the Epistem Genedrive®, MolbioTruenat™, and Xpert&#xD;
           MTB/RIF tests&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of tests</measure>
    <time_frame>4 months</time_frame>
    <description>Non-inferiority of Epistem Genedrive® MTB iD Test and MolBio Truenat™ TB Assay to GeneXpert MTB/RIF using a non-inferiority margin of 5% for sensitivity in smear-positive, culture-positive; 7% for overall C+ sensitivity; and 3% for specificity in smear-negative, culture-negatives</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity and specificity of Epistem Genedrive® MTB iD</measure>
    <time_frame>4 months</time_frame>
    <description>Sensitivity and specificity of Epistem Genedrive® MTB iD Test on raw sputum before homogenization, homogenized raw sputum and sputum pellet against a gold standard of concentrated smear and four cultures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity and specificity of MolBio Truenat™ TB Assay</measure>
    <time_frame>4 months</time_frame>
    <description>Sensitivity and specificity of MolBio Truenat™ TB Assay on homogenized raw sputum and sputum pellet against a gold standard of concentrated smear and four cultures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure rate for the Epistem Genedrive® system assay and for the MolBio Truenat™ assay</measure>
    <time_frame>10 months</time_frame>
    <description>Failure rate for the Epistem Genedrive® system assay and for the MolBio Truenat™ assay, expressed as the proportion of tests that require repeating due to an indeterminate or uninterpretable initial result (separately and together for tests performed on raw sputum and sputum pellet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Training needs for each assay</measure>
    <time_frame>10 months</time_frame>
    <description>Training needs for each assay assessed objectively by number of hours of training, number of runs required, and successful completion of a proficiency assessment by trainees; training needs also will be assessed subjectively by the trainers and by user questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operational feasibility</measure>
    <time_frame>10 months</time_frame>
    <description>Operational feasibility will be assessed according to the infrastructure required to support each test, the robustness of the reagents and equipment (any breakdowns, storage requirements or contamination events), and the time it takes to run each test;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-comparison between assays</measure>
    <time_frame>10 months</time_frame>
    <description>A cost-comparison between assays assessing the cost per sample run incorporating all costs involved in transport, equipment, reagents, personnel, etc. will be performed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">504</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Investigational</arm_group_label>
    <description>• Participants will be asked to provide a total of three sputum samples over Days 1 and 2. The intent is for all samples to be collected before the subject starts any form of TB treatment. The first specimen (S1) should be 2 ml or greater in volume, and the second and third specimens (S2 and S3) should each be 1 ml or greater in volume. On Day 1, each participant will be asked to submit one spot sputum (S1) after enrollment and a second spot sputum after at least 2 hours (S2). Participants will be instructed to come back the following day (Day 2) and provide a third spot sputum (S3). In the event that a participant fails to return on Day 2, S3 may be collected a maximum of 7 days after enrollment, provided that no TB treatment has been initiated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Epistem Genedrive® and MolBio Truenat™</intervention_name>
    <description>S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.</description>
    <arm_group_label>Investigational</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with clinical suspicion of pulmonary TB.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Clinical suspicion of pulmonary TB (including cough ≥2 weeks and at least 1 other&#xD;
             symptom typical of TB);&#xD;
&#xD;
               -  Age 18 years or above;&#xD;
&#xD;
               -  Willingness to have a study follow-up visit, if necessary, approximately two&#xD;
                  months after enrollment&#xD;
&#xD;
               -  Willingness to provide 3 sputum specimens at enrollment&#xD;
&#xD;
               -  Provision of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Receipt of ≥48 cumulative hours OR three or more doses of anti-TB treatment (defined&#xD;
             as combination anti-TB therapy intended to treat active TB) within 60 days prior to&#xD;
             completion of sputum collection;&#xD;
&#xD;
               -  Inability to provide informed consent (e.g. mentally impaired)&#xD;
&#xD;
               -  Enrolled individuals who do not provide a first sputum sample of ≥ 2ml and a&#xD;
                  second and third sputum sample of ≥ 1ml each will be classified as early&#xD;
                  exclusions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2014</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02252198
org study id: NA_00085221
secondary id: NA_00085221
nct id: NCT02252198
lead sponsor: 
collaborator: 
has dmc: No
Assess sensitivity and specificity of two nucleic acid amplification tests, namely Epistem
      Genedrive® and MolbioTruenat™ in raw sputum compared to the WHO-endorsed GeneXpert® MTB/RIF
      assay using a gold standard of four cultures
-  Estimate the accuracy of the Epistem Genedrive® and MolbioTruenat™ in raw sputum and in
           sputum pellets.

        -  Assess the operational feasibility of Epistem Genedrive® and MolbioTruenat™

        -  Determine and compare costs between the Epistem Genedrive®, MolbioTruenat™, and Xpert
           MTB/RIF tests
observational model: Cohort
time perspective: Prospective
measure: Non-inferiority of tests
time frame: 4 months
description: Non-inferiority of Epistem Genedrive® MTB iD Test and MolBio Truenat™ TB Assay to GeneXpert MTB/RIF using a non-inferiority margin of 5% for sensitivity in smear-positive, culture-positive; 7% for overall C+ sensitivity; and 3% for specificity in smear-negative, culture-negatives
measure: Sensitivity and specificity of Epistem Genedrive® MTB iD
time frame: 4 months
description: Sensitivity and specificity of Epistem Genedrive® MTB iD Test on raw sputum before homogenization, homogenized raw sputum and sputum pellet against a gold standard of concentrated smear and four cultures.
measure: Sensitivity and specificity of MolBio Truenat™ TB Assay
time frame: 4 months
description: Sensitivity and specificity of MolBio Truenat™ TB Assay on homogenized raw sputum and sputum pellet against a gold standard of concentrated smear and four cultures.
measure: Failure rate for the Epistem Genedrive® system assay and for the MolBio Truenat™ assay
time frame: 10 months
description: Failure rate for the Epistem Genedrive® system assay and for the MolBio Truenat™ assay, expressed as the proportion of tests that require repeating due to an indeterminate or uninterpretable initial result (separately and together for tests performed on raw sputum and sputum pellet
measure: Training needs for each assay
time frame: 10 months
description: Training needs for each assay assessed objectively by number of hours of training, number of runs required, and successful completion of a proficiency assessment by trainees; training needs also will be assessed subjectively by the trainers and by user questionnaires
measure: Operational feasibility
time frame: 10 months
description: Operational feasibility will be assessed according to the infrastructure required to support each test, the robustness of the reagents and equipment (any breakdowns, storage requirements or contamination events), and the time it takes to run each test;
measure: Cost-comparison between assays
time frame: 10 months
description: A cost-comparison between assays assessing the cost per sample run incorporating all costs involved in transport, equipment, reagents, personnel, etc. will be performed.
arm group label: Investigational
description: • Participants will be asked to provide a total of three sputum samples over Days 1 and 2. The intent is for all samples to be collected before the subject starts any form of TB treatment. The first specimen (S1) should be 2 ml or greater in volume, and the second and third specimens (S2 and S3) should each be 1 ml or greater in volume. On Day 1, each participant will be asked to submit one spot sputum (S1) after enrollment and a second spot sputum after at least 2 hours (S2). Participants will be instructed to come back the following day (Day 2) and provide a third spot sputum (S3). In the event that a participant fails to return on Day 2, S3 may be collected a maximum of 7 days after enrollment, provided that no TB treatment has been initiated.
intervention type: Other
intervention name: Epistem Genedrive® and MolBio Truenat™
description: S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
arm group label: Investigational
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
facility: 
country: United States
responsible party type: Sponsor
mesh term: Tuberculosis